Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

NCT06964906 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

ER+/HER2- Breast Cancer

Interventions

PROCEDURE: HIFU
DRUG: Toripalimab
DRUG: nab-Paclitaxel (nab-P)
DRUG: Epirubicin (E)
DRUG: Cyclophosphamide (C)

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University